Shield Therapeutics Share Discussion Threads

[powerp2] 10/12/2020 07:55

Not the news i was expecting
This Board never ceases to surprise and not in a good way.
If the sales need is bad when released in January this will tank.
What they have announced isn't a potential tweak of strategy but a complete turnabout - why wasn't this approach figure when doing deals with Norgine and in China? I wonder if it will be tripped out of sales are as disappointing as I fear.
Happy Christmas everyone!

[markinvestor] 10/12/2020 07:35

Both Peel Hunt and Finncap reiterate their price targets

[best1467] 10/12/2020 07:26

Regarding funding they will require fundraise for a proportion plus they need funds for the p3 trial which needs to start feb I think .

[1gw] 10/12/2020 07:26

Surprised there isn't a change at the top as a result of this. Sounds like they picked the wrong shortlist to try to finalise terms with. Sh*t happens I suppose.

[best1467] 10/12/2020 07:22

Flabbergasted and the comment that sums the board up we have learnt a lot we know that Ferracru as advantages in a Pandemic as they don’t need to attend hospital amazing what’s been achieved in 15 months well done the board.
Would imagine we will be looking at sub £1 today possibly considerably worse

[nobbygnome] 10/12/2020 07:14

Well well. At least we have an update and as promised by Tim they are getting money from debt not a fund raising in the short term. You do have to wonder what on earth the problem is in signing a deal but at least they appear to have options.

I think the major aspect is no fund raise which is good for the market but clearly further delays are not.

[waterloo01] 10/12/2020 07:13

Oh. Not what the doctor ordered.

[parc1] 09/12/2020 20:10

Proactive Research analyst Emma Ulker, 10 Aug 2020

"the long term clinical durability of Feraccru (to be called Accrufer in US), its cost, efficacy and ease-of-use when compared to the standard IV iron, support discussions with potential US partners."

[parc1] 09/12/2020 18:45

from 06 Aug 2020

"Shield plans to publish the full AEGIS-H2H study results in a peer-reviewed paper in due course."

but the important points have already been highlighted:

Long term phase (using the ITT results)

* By week 24, 65% Feraccru®/Accrufer® of those patients still being monitored had achieved normal levels of Hb(2) and therefore were non-anaemic,
compared with 68% of IV patients.

* At weeks 24, 36 and 52, the mean increases in Hb levels in those patients still being monitored were:
2.93 g/dL, 3.16 g/dL and 2.72 g/dL in the Feraccru®/Accrufer® arm
compared with 2.84 g/dL, 2.70 g/dL and 2.79 g/dL in the IV arm.

"results..demonstrate that Feraccru®/Accrufer® compares favourably with IV therapy"

Feraccru Capsules are the way forward, leaving IV behind.

Feraccru is safer and less expensive*

* The higher cost of IV FCM is driven by higher drug cost and costs of IV administration.

"A licensing deal in the US for Accrufer can start to unlock the world’s largest iron replacement market which represents c70% of the estimated US$3Bn value of the global market."

Tim Watts over-promised on the estimated time for signing US deal - a deal which will triple Shield's market. I would think news on progress will arrive by mid-December, 3 months following Tim's proactive interview.

The deal will be done. The product is excellent. Patience required.

[lako42] 09/12/2020 12:29

Sadly that is very true.

[powerp2] 09/12/2020 12:14

Don't kick yourself too hard Lako. If you stuck rigidly to the attractive Board requirement these days there wouldn't be much left to invest in!

[shandypants2] 09/12/2020 10:08

CEO pay - looking at 2019 report ex CEO Carl Sterritt received over £550k last year (despite annual revenues being only £0.7m) which included a £190k bonus. The previous year his bonus was an eye watering £283k.
According to the remuneration committee notes the bonus is linked to the achievement of strategic objectives.
Well the No1 strategic objective for 2020 is an US commercial agreement so if Tim wants his bonus then he needs to get this sorted in the next 2 weeks!!!
Also his employment terms are interesting, appears he has been promoted to CEO exclusively to get the US deal over the line : Note 1 – Tim Watts is appointed under a twelve-month fixed term contract with no right of early termination other than following a US out-licensing or
similar transaction in which case he is entitled to terminate his contract with four months’ notice.

[onceaday] 08/12/2020 14:41

Powerp2 - thanks for attempting to answer the question. Hopefully, someone at Shield is taking note.

[powerp2] 08/12/2020 13:47

I e mailed to ask about the Aegis H2H study and a request for more communication - this can be achieved without crossing any Market rules the usual excuse
Regrettably i only got a response from PR firm which said publishing the study takes time and they'd pass on the comments.
Unsurprisingly hopeless!
I'm afraid the conclusion i have come to is they aren't too bothered keeping the retail small shareholders in the loop and focus on the institutional boys who hold about 70% i think.

[lovewinshatelosses] 08/12/2020 11:57

This feels like it's going to drift all the way back down to mid 80's. Foolishly had a small top up last week. When will I learn the art of patience?!

[ekcs] 08/12/2020 11:49

The applications for pricing don't need a peer-reviewed publication as the authorites will look at confidential documents generally. Once pricing is approved however, the commercial partner's reps will need the article to be able to promote. So, as pricing reviews take time, they have time to get it published

[whatno] 08/12/2020 10:35

Has anyone asked the Company when the Aegis-H2H study is being published for peer review? I thought the European marketing strategy is intended to be based on the health economics demonstrated in that study but to have any credibility it needs to be published in a reputable scientific journal not just sent out in a press release.

[best1467] 08/12/2020 09:48

Guys that was a Tongue in Cheek comment but it just shows how ridiculous the situation is that we are even contemplating product manufactured could go out of date prior to a deal signed with such a long shelf life.
Commenting on this company is becoming hard work and repetitive the European rollout is snail pace at best no communication with Nordgine on market penetration it’s a sad situation from what looked and still should be a Exciting growth stock.Disappointing

[ekcs] 08/12/2020 00:56

and the 21 months is just the finished product. Bulk substance has shelf life also, so both need to be considered. Basically it looks like they don't have to worry too much about product going off (plus there is clearly a healthy margin). They simply (!! LOL) need to finalise and annouce a deal as soon as possible.

[parc1] 07/12/2020 23:27

Lako42, going by what Tim said on timing:

"launch stocks should be available by around the end of this year" - well we should hopefully get news on that this year.

"launch some time in this first half of next year" - that is expected.

Tim is confident of a deal. There are numerous companies in talks. Like you, I am keen to see the deal done soon.

Best, I just checked Ferracru: shelf life 21 months. Given that you said
"( Let’s hope the shelf life is still ok )" yes I really hope so! LOL

[lako42] 07/12/2020 21:18

Let's be honest, another slip in deadline of a deal would be unacceptable. I see people are now realising it isn't coming this year and are repositioning.

Another delay is a complete failure on behalf of the company.

[best1467] 07/12/2020 20:53

The advanced manufacturing of product is old news it was stated several months ago that they had put in place the necessary order for the Nordgine needs and also USA in expectation of the licensing deal ( Let’s hope the shelf life is still ok )

[shandypants2] 07/12/2020 16:47

i still think they are hopeful of a deal this side of xmas, but as you say one in January would not be a major issue - although as this date has slipped twice already Tim will clearly want to avoid a 3rd if at all possible.
In terms of the advanced manufacturing, as this is undertaken in France it may be partly to avoid Brexit issues, as much as wanting to be ready once the US deal is finalised.
2020 has been a very frustrating year for LTH so lets hope we can finish on a high

[parc1] 07/12/2020 09:21

Transcription snapshot Sep 15 2020 (just to recap)

Katie, Proactive

"Let's talk about the US commercialisation. What's happening there?"

Tim Watts

"So we are still working hard on that. We have had multiple companies interested. We have had a good proportion of those sign confidentiality agreements and [they] have got a lot of confidential data pertaining to the US from us. A good number of those then moved towards agreeing term sheets and we have had and still have ongoing discussions with a number of companies. So we are making progress. I think I have said in the past I had hoped we would perhaps have had it done by the end of September but I think that is probably not going to happen but we remain very confident about getting a partner in the US so much so that we have actually ordered the launch stocks for the US from our manufacturing partner and those launch stocks should be available by around the end of this year for launch some time in this first half of next year so we are confident that we are going to get there. We are working hard on it but it hasn't happened yet and inevitably with the sort of confidentiality issues there is a limit to what I can say about that."
_____________________________

So from the discussions with the potential partner companies, Shield have a firm
idea on initial quantities of stock required and have ordered them, reducing time to market. A deal could be signed in January without much affect on where we would have been. As soon as that deal is signed, the partner's sales team will be released with the knowledge of product availability.